BDSX vs ONCO vs EXAS vs AGEN

For growth investors, Biodesix, Inc.

(BDSX) is the stronger pick with 24. 1% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). Analysts rate Biodesix, Inc. (BDSX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Exact Sciences Corporation (EXAS) delivered a total return of +6.

1%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: EXAS returned +1669% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 4810% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Biodesix, Inc.

(BDSX) is pulling ahead at 24. 1% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to 29. 2% for Biodesix, Inc.. Over a 3-year CAGR, BDSX leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXAS leads at -6. 4% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 2. 9x forward P/E versus 582. 8x for Exact Sciences Corporation — 579. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 91. 9% to $7. 33.

In this comparison, ONCO (34.

1% yield) pays a dividend. BDSX, EXAS, AGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDSX is a small-cap high-growth stock; ONCO is a small-cap income-oriented stock; EXAS is a mid-cap high-growth stock; AGEN is a small-cap quality compounder stock. ONCO pays a dividend while BDSX, EXAS, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.